Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2014

Open Access 01-12-2014 | Review

Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group

Authors: Anna Merlotti, Daniela Alterio, Riccardo Vigna-Taglianti, Alessandro Muraglia, Luciana Lastrucci, Roberto Manzo, Giuseppina Gambaro, Orietta Caspiani, Francesco Miccichè, Francesco Deodato, Stefano Pergolizzi, Pierfrancesco Franco, Renzo Corvò, Elvio G Russi, Giuseppe Sanguineti

Published in: Radiation Oncology | Issue 1/2014

Login to get access

Abstract

Performing intensity-modulated radiotherapy (IMRT) on head and neck cancer patients (HNCPs) requires robust training and experience. Thus, in 2011, the Head and Neck Cancer Working Group (HNCWG) of the Italian Association of Radiation Oncology (AIRO) organized a study group with the aim to run a literature review to outline clinical practice recommendations, to suggest technical solutions and to advise target volumes and doses selection for head and neck cancer IMRT. The main purpose was therefore to standardize the technical approach of radiation oncologists in this context. The following paper describes the results of this working group. Volumes, techniques/strategies and dosage were summarized for each head-and-neck site and subsite according to international guidelines or after reaching a consensus in case of weak literature evidence.
Appendix
Available only for authorised users
Literature
1.
Bekelman JE, Wolden S, Lee N: Head-and-neck target delineation among radiation oncology residents after a teaching intervention: a prospective, blinded pilot study. Int J Radiat Oncol Biol Phys. 2009, 73: 416-423.PubMed
2.
Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol Off J Am Soc Clin Oncol. 2010, 28: 2996-3001.
3.
Pignon J-P, le Maître A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009, 92: 4-14.PubMed
4.
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS: Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013, 31: 845-852.PubMedCentralPubMed
5.
Brierley R: ASCO annual meeting. Lancet Oncol. 2012, 2012 (13): 665-666.
6.
Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JMG, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D’Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008, 26: 3138-3146.PubMedCentralPubMed
7.
Worden FP, Moyer J, Lee JS, Taylor JMG, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Hogikyan N, Lassig AAD, Emerick K, Mukherji S, Hadjiski L, Tsien CI, Miller TH, Wallace NE, Mason HL, Bradford CR, Wolf GT: Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope. 2009, 119: 1510-1517.PubMedCentralPubMed
8.
Cohen EE, Karrison T, Kocherginsky M, Huang CH, Aguinik M, Mittal BB, Yunus F, Samant S, Brockstein B, Raez LE, Mehra R, Kumar P, Ondrey FG, Seiwert TY, Villaflor Meucci Vittoria, Haraf D, Vokes EE: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 2012:suppl; abstr 5500.,
9.
Haddad RI, Rabinowits G, Tishler RB, Adkins D, Khuri, Clark J, Lorch JH, Limaye S, Wirth LJ, O’Neill A, Riley S, Posner MR: The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report. J Clin Oncol (Meeting Abstracts) 2012:astr. 5501.
10.
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, Raucourt D de, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013, 31:853–859.
11.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11: 21-28.PubMed
12.
Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meet Abstr. 2011, 29: 5500-
13.
Chan JYK, Sanguineti G, Richmon JD, Marur S, Gourin CG, Koch W, Chung CH, Quon H, Bishop JA, Aygun N, Agrawal N: Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2012, 138: 1040-1046.PubMedCentralPubMed
14.
Deasy JO, Moiseenko V, Marks L, Chao KSC, Nam J, Eisbruch A: Radiotherapy Dose-Volume effects on salivary gland function. Int J Radiat Oncol. 2010, 76 (3, Supplement 1): S58-S63.
15.
Mohan R, Wu Q, Manning M, Schmidt-Ullrich R: Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol. 2000, 46: 619-630.
16.
Eisbruch A, Foote RL, O’Sullivan B, Beitler JJ, Vikram B: Intensity-modulated radiation therapy for head and neck cancer: Emphasis on the selection and delineation of the targets. Semin Radiat Oncol. 2002, 12: 238-249.PubMed
17.
Eisbruch A, Harris J, Garden AS, Chao CKS, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK: Multi-Institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00–22). Int J Radiat Oncol. 2010, 76: 1333-1338.
18.
Sanguineti G, Gunn GB, Endres EJ, Chaljub G, Cheruvu P, Parker B: Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol. 2008, 72: 737-746.
19.
Eisbruch A: Intensity-modulated radiotherapy of head-and-neck cancer: encouraging early results. Int J Radiat Oncol. 2002, 53: 1-3.
20.
Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol. 2009, 27: 3684-3690.PubMedCentralPubMed
21.
Montejo ME, Shrieve DC, Bentz BG, Hunt JP, Buchman LO, Agarwal N, Hitchcock YJ: IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol. 2011, 81: e845-e852.
22.
Morganti AG, Mignogna S, Deodato F, Massaccesi M, Cilla S, Calista F, Serafini G, Digesú C, Macchia G, Picardi V, Caravatta L, Di Lullo L, Giglio G, Sallustio G, Piermattei A, Cellini N, Valentini V: Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer. Int J Radiat Oncol. 2011, 79: 1073-1080.
23.
Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot J-C, Le Maître A, Pajak TF, Poulsen MG, O’Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon J-P: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006, 368: 843-854.PubMed
24.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol. 2000, 48: 7-16.
25.
Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet. 2003, 362: 933-940.PubMed
26.
Ang K, Pajak T, Wheeler R, Rosenthal D, Nguyen-Tan F, Lu C, Kim H, Axelrod R, Silverman C, Weber R: A phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of efficacy and toxicity. Int J Radiat Oncol. 2010, 77: 1-2.
27.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A: Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99–02): an open-label phase 3 randomised trial. Lancet Oncol. 2012, 13: 145-153.PubMed
28.
Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT: Randomized phase ii trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009, 27: 242-249.PubMed
29.
Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS: Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol. 2009, 75: 725-733.
30.
Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H, Peters LJ: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001, 51: 571-578.PubMed
31.
Sanguineti G, Richetti A, Bignardi M, Corvo’ R, Gabriele P, Sormani MP, Antognoni P: Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys. 2005, 61: 762-771.PubMed
32.
Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL: Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol. 2008, 70: 322-329.
33.
Lo EJ, Bell D, Woo JS, Li G, Hanna EY, El-Naggar AK, Sturgis EM: Human papillomavirus and WHO type I nasopharyngeal carcinoma. Laryngoscope. 2010, 120: 1990-1997.PubMedCentralPubMed
34.
Neubauer E, Dong L, Followill DS, Garden AS, Court LE, White RA, Kry SF: Assessment of shoulder position variation and its impact on IMRT and VMAT doses for head and neck cancer. Radiat Oncol. 2012, 7: 19-PubMedCentralPubMed
35.
ICRU: Prescribing, Recording and Reporting Photon Beam Therapy. Report 50. 1993, International Commission on Radiation Units and Measurements, Washington, DC
36.
ICRU: Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT): Contents. Oxford University Press. J ICRU 2010, 10:NP.
37.
Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol. 2000, 47: 551-560.
38.
ICRU: 4. Definition of Volumes — JOURNAL OF THE ICRU. ICRU Rep 83. Volume 10. 2010, Oxford University Press, Oxford
39.
Geets X, Daisne J-F, Tomsej M, Duprez T, Lonneux M, Grégoire V: Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiother Oncol. 2006, 78: 291-297.PubMed
40.
Geets X, Tomsej M, Lee JA, Duprez T, Coche E, Cosnard G, Lonneux M, Grégoire V: Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: Impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol. 2007, 85: 105-115.PubMed
41.
Chao KSC, Wippold FJ, Ozyigit G, Tran BN, Dempsey JF: Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol. 2002, 53: 1174-1184.
42.
Wambersie A, Landgerg T: ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy. ICRU Publ Bethesda MD 1999.
43.
Berthelsen AK, Dobbs J, Kjellén E, Landberg T, Möller TR, Nilsson P, Specht L, Wambersie A: What’s new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice?. Cancer Imaging Off Publ Int Cancer Imaging Soc. 2007, 7: 104-116.
44.
Hu KS, Quon H, Harrison L: Management of the Neck: Radiation Therapy and Chemotherapy. Head Neck Cancer Multidiscip Approach. 2009, Lippincott Williams & Wilkins, Philadelphia, 204-231. 3
45.
Grégoire V, Coche E, Cosnard G, Hamoir M, Reychler H: Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol. 2000, 56: 135-150.PubMed
46.
Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H: CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol. 2003, 69: 227-236.PubMed
47.
Grégoire V, Eisbruch A, Hamoir M, Levendag P: Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006, 79: 15-20.PubMed
48.
Ben David, Merav, Eisbruch, Avraham: Delineating neck targets for intensity- modulated radiation therapy of head and neck cancer what have we learned from marginal recurrences?. In IMRT IGRT SBRT Adv Treat Plan Deliv Radiother. Edited by Meyer J. Basel: Karger Publishers; 2007:193–207.
49.
Chen AM, Farwell DG, Luu Q, Donald PJ, Perks J, Purdy JA: Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance?. Int J Radiat Oncol Biol Phys. 2011, 81: 943-949.PubMed
50.
Eisbruch A, Gregoire V: Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer. Semin Radiat Oncol. 2009, 19: 43-52.PubMedCentralPubMed
51.
Rao NG, Sanguineti G, Chaljub G, Newlands SD, Qiu S: Do neck levels negative on initial CT need to be dissected after definitive radiation therapy with or without chemotherapy?. Head Neck. 2008, 30: 1090-1098.PubMed
52.
Van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, Meyer CJ, Snow GB: Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990, 177: 379-384.PubMed
53.
Apisarnthanarax S, Elliott DD, El-Naggar AK, Asper JA, Blanco A, Ang KK, Garden AS, Morrison WH, Rosenthal D, Weber RS, Chao KSC: Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol. 2006, 64: 678-683.
54.
Yao M, Nguyen T, Buatti JM, Dornfeld KJ, Tan H, Wacha J, Bayouth JE, Clamon GH, Funk GF, Smith RB, Chang K, Hoffman HT: Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research. Am J Clin Oncol. 2006, 29: 606-612.PubMed
55.
Weiss MH, Harrison LB, Isaacs R: USe of decision analysis in planning a management strategy for the stage no neck. Arch Otolaryngol Neck Surg. 1994, 120: 699-702.
56.
Lapeyre M, Toledano I, Bourry N, Bailly C, Cachin F: Délinéation des volumes cibles des cancers des voies aérodigestives supérieures en radiothérapie conformationnelle avec modulation d’intensité. Cancer/Radiothérapie. 2011, 15: 466-472.
57.
Vorwerk H, Hess CF: Guidelines for delineation of lymphatic clinical target volumes for high conformal radiotherapy: head and neck region. Radiat Oncol. 2011, 6: 1-25.
58.
Augurio A, Pilla AD, Tartaro A: Head and Neck Lymph Nodes. In A Guide for Delineation of Lymph Nodal Clinical Target Volume in Radiation Therapy. Edited by Ausili Cèfaro G, Genovesi D, Perez CA, Vinciguerra A. Springer Berlin Heidelberg; 2008:63–95.
59.
Sanguineti G, Culp LR, Endres EJ, Bayouth JE: Are neck nodal volumes drawn on CT slices covered by standard three-field technique?. Int J Radiat Oncol. 2004, 59: 725-742.
60.
Hall WH, Guiou M, Lee NY, Dublin A, Narayan S, Vijayakumar S, Purdy JA, Chen AM: Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2008, 72: 1362-1367.PubMed
61.
Sanguineti G, Adapala P, Endres EJ, Brack C, Fiorino C, Sormani MP, Parker B: Dosimetric Predictors of Laryngeal Edema. Int J Radiat Oncol. 2007, 68: 741-749.
62.
Lee N, Mechalakos J, Puri DR, Hunt M: Choosing an intensity-modulated radiation therapy technique in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2007, 68: 1299-1309.PubMed
63.
Takamiya R, Missett B, Weinberg V, Akazawa C, Akazawa P, Zytkovicz A, Bucci MK, Lee N, Quivey JM, Xia P: Simplifying intensity-modulated radiotherapy plans with fewer beam angles for the treatment of oropharyngeal carcinoma. J Appl Clin Med Phys Am Coll Med Phys. 2007, 8: 26-36.
64.
Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma–the University of Iowa experience. Int J Radiat Oncol Biol Phys. 2005, 63: 410-421.PubMed
65.
Dabaja B, Salehpour MR, Rosen I, Tung S, Morrison WH, Ang KK, Garden AS: Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: comparison of split-field and whole-field techniques. Int J Radiat Oncol Biol Phys. 2005, 63: 1000-1005.PubMed
66.
Fiorino C, Dell’Oca I, Pierelli A, Broggi S, Martin ED, Muzio ND, Longobardi B, Fazio F, Calandrino R: Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol. 2006, 78: 276-282.PubMed
67.
Clemente S, Wu B, Sanguineti G, Fusco V, Ricchetti F, Wong J, McNutt T: SmartArc-based volumetric modulated Arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy. Int J Radiat Oncol. 2011, 80: 1248-1255.
68.
Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2003, 66: 253-262.
69.
Sanguineti G, Ricchetti F, Wu B, Agrawal N, Gourin C, Agbahiwe H, Marur S, Clemente S, McNutt T, Forastiere A: Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy. Head Neck. 2012, 34: 1640-1647.PubMedCentralPubMed
70.
Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P: Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol. 2006, 64: 355-362.
71.
Ricchetti F, Wu B, McNutt T, Wong J, Forastiere A, Marur S, Starmer H, Sanguineti G: Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. Int J Radiat Oncol. 2011, 80: 161-168.
72.
Koyfman SA, Adelstein DJ: Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. Int J Radiat Oncol. 2012, 84: 581-589.
73.
Li H, Zhu XR, Zhang L, Dong L, Tung S, Ahamad A, Chao KSC, Morrison WH, Rosenthal DI, Schwartz DL, Mohan R, Garden AS: Comparison of 2D radiographic images and 3D cone beam computed tomography for positioning head-and-neck radiotherapy patients. Int J Radiat Oncol Biol Phys. 2008, 71: 916-925.PubMed
74.
Kim Y, Tomé WA, Bal M, McNutt TR, Spies L: The impact of dental metal artifacts on head and neck IMRT dose distributions. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2006, 79: 198-202.
75.
Yang C, Liu T, Jennelle RL, Ryu JK, Vijayakumar S, Purdy JA, Chen AM: Utility of megavoltage Fan-beam CT for treatment planning in a head-and-neck cancer patient with extensive dental fillings undergoing helical tomotherapy. Med Dosim. 2010, 35: 108-114.PubMed
76.
Jeraj R, Keall P: The effect of statistical uncertainty on inverse treatment planning based on Monte Carlo dose calculation. Phys Med Biol. 2000, 45: 3601-PubMed
77.
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E: Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011, 12: 127-136.PubMedCentralPubMed
78.
Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, Morrison WH, Weber RS, Garden AS, Frankenthaler RA: Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial☆☆☆. Int J Radiat Oncol. 1993, 26: 3-11.
79.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004, 350: 1945-1952.PubMed
80.
Tandon S, Munir N, Roland NJ, Lancaster J, Jackson SR, Jones TM: A systematic review and Number Needed to Treat analysis to guide the management of the neck in patients with squamous cell carcinoma of the head and neck. Auris Nasus Larynx. 2011, 38: 702-709.PubMed
81.
Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO: Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol. 2010, 76 (3, Supplement 1): S10-S19.
82.
Yao M, Chang K, Funk GF, Lu H, Tan H, Wacha J, Dornfeld KJ, Buatti JM: The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy-the university of iowa experience. Int J Radiat Oncol Biol Phys. 2007, 67: 1332-1341.PubMed
83.
Daly ME, Le Q-T, Kozak MM, Maxim PG, Murphy JD, Hsu A, Loo BW, Kaplan MJ, Fischbein NJ, Chang DT: Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. Int J Radiat Oncol. 2011, 80: 1412-1422.
84.
Scholl P, Byers RM, Batsakis JG, Wolf P, Santini H: Microscopic cut-through of cancer in the surgical treatment of squamous carcinoma of the tongue. Am J Surg. 1986, 152: 354-360.PubMed
85.
Vergeer MR, Doornaert PAH, Jonkman A, Kaanders JHAM, van den Ende PLA, de Jong MA, Leemans CR, Slotman BJ, Langendijk JA: Ipsilateral irradiation for oral and oropharyngeal carcinoma treated with primary surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2010, 78: 682-688.PubMed
86.
Werner JA, Dünne AA, Myers JN: Functional anatomy of the lymphatic drainage system of the upper aerodigestive tract and its role in metastasis of squamous cell carcinoma. Head Neck. 2003, 25: 322-332.PubMed
87.
Byers RM, Weber RS, Andrews T, McGill D, Kare R, Wolf P: Frequency and therapeutic implications of “skip metastases” in the neck from squamous carcinoma of the oral tongue. Head Neck. 1997, 19: 14-19.PubMed
88.
Chao CKS, Perez CA, Brady LW: Oral Cavity. Radiat Oncol Manag Decis. 2011, LWW, Philadelphia, 247-258. 3
89.
Hansen EK, Yom SS, Chen CP, Schechter NR: Cancer of the lip and Oral Cavity. Handb Evid-Based Radiat Oncol. 2nd ed. Edited by: Hansen E, III MR. 2010, Springer, New York, 131-144. 2010
90.
Larsen SR, Johansen J, Sørensen JA, Krogdahl A: The prognostic significance of histological features in oral squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2009, 38: 657-662.
91.
Yuen AP, Lam KY, Wei WI, Lam KY, Ho CM, Chow TL, Yuen WF: A comparison of the prognostic significance of tumor diameter, length, width, thickness, area, volume, and clinicopathological features of oral tongue carcinoma. Am J Surg. 2000, 180: 139-143.PubMed
92.
Cole I, Hughes L: The relationship of cervical lymph node metastases to primary sites of carcinoma of the upper aerodigestive tract: a pathological study. Aust N Z J Surg. 1997, 67: 860-865.PubMed
93.
Shah JP, Candela FC, Poddar AK: The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990, 66: 109-113.PubMed
94.
Rasch C, Keus R, Pameijer FA, Koops W, de Ru V, Muller S, Touw A, Bartelink H, van Herk M, Lebesque JV: The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol. 1997, 39: 841-848.
95.
Sham JS, Cheung YK, Choy D, Chan FL, Leong L: Nasopharyngeal carcinoma: CT evaluation of patterns of tumor spread. AJNR Am J Neuroradiol. 1991, 12: 265-270.PubMed
96.
Orlandi E, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa F, Licitra L, Pignoli E, Fallai C: Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. Future Oncol Lond Engl. 2013, 9: 103-114.
97.
Sham J, Choy D, Kwong PW, Cheng AC, Kwong DL, Yau CC, Wan KY, Au GK: Radiotherapy for nasopharyngeal carcinoma: shielding the pituitary may improve therapeutic ratio. Int J Radiat Oncol Biol Phys. 1994, 29: 699-704.PubMed
98.
Shanmugaratnam KS, Sobin LH: Histological typing of upper respiratory tract tumors Geneva. 1978.
99.
Chan J, Bray F, McCarron P: Nasopharyngeal carcinoma. In Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Edited by Barnes L, Eveson JW, Reichart PA, Sidransky D. Lyon, France: IARC Press; 2005:85–97.
100.
Tse LA, Yu IT-S, Mang OW-K, Wong S-L: Incidence rate trends of histological subtypes of nasopharyngeal carcinoma in Hong Kong. Br J Cancer. 2006, 95: 1269-1273.PubMedCentralPubMed
101.
Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N: Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995, 146: 1355-1367.PubMedCentralPubMed
102.
Ruckenstein MJ: Nasopharyngeal Carcinoma. Compr Rev Otolaryngol. 2004, W.B. Saunders, Philadelphia, 197-198.
103.
Lee JT, Ko CY: Has survival improved for nasopharyngeal carcinoma in the United States?. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2005, 132: 303-308.
104.
Reddy SP, Raslan WF, Gooneratne S, Kathuria S, Marks JE: Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol. 1995, 16: 103-108.PubMed
105.
Kim K, Wu H-G, Kim HJ, Sung M-W, Kim KH, Lee S-H, Heo DS, Kim HJ, Park C: Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2009, 31: 1121-1128.PubMed
106.
Peponi E, Glanzmann C, Kunz G, Renner C, Tomuschat K, Studer G: Simultaneous integrated boost intensity‑modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlenther Onkol. 2010, 186: 135-142.PubMed
107.
Dubrulle F, Souillard R, Hermans R: Extension patterns of nasopharyngeal carcinoma. Eur Radiol. 2007, 17: 2622-2630.PubMed
108.
King AD, Lam WW, Leung SF, Chan YL, Teo P, Metreweli C: MRI of local disease in nasopharyngeal carcinoma: tumour extent vs tumour stage. Br J Radiol. 1999, 72: 734-741.PubMed
109.
Kong L, Zhang Y-W, Hu C-S, Guo Y: Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin J Cancer. 2010, 29: 551-555.PubMed
110.
Hunt MA, Zelefsky MJ, Wolden S, Chui C-S, LoSasso T, Rosenzweig K, Chong L, Spirou SV, Fromme L, Lumley M, Amols HA, Ling CC, Leibel SA: Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol. 2001, 49: 623-632.
111.
Lo SS, Lu JJ: Natural History, Presenting Symptoms, and Diagnosis of Nasopharyngeal Carcinoma. In Nasopharyngeal Cancer. Edited by Lu JJ, Cooper JS, Lee AWM. Berlin Heidelberg: Springer Berlin Heidelberg; 2010:41–51. [Medical Radiology].
112.
Pan W-R, Suami H, Corlett RJ, Ashton MW: Lymphatic drainage of the nasal fossae and nasopharynx: preliminary anatomical and radiological study with clinical implications. Head Neck. 2009, 31: 52-57.PubMed
113.
Wang X, Li L, Hu C, Zhou Z, Ying H, Ding J, Feng Y: Patterns of level II node metastasis in nasopharyngeal carcinoma. Radiother Oncol. 2008, 89: 28-32.PubMed
114.
Mukherji SK, Armao D, Joshi VM: Cervical nodal metastases in squamous cell carcinoma of the head and neck: What to expect. Head Neck. 2001, 23: 995-1005.PubMed
115.
Ho FC, Tham IW, Earnest A, Lee K, Lu JJ: Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence. BMC Cancer. 2012, 12: 98-PubMedCentralPubMed
116.
Wang XS, Hu CS, Ying HM, Zhou ZR, Ding JH, Feng Y: Patterns of Retropharyngeal Node Metastasis in Nasopharyngeal Carcinoma. Int J Radiat Oncol. 2009, 73: 194-201.
117.
Lee AW, Sham JS, Poon YF, Ho JH: Treatment of stage I nasopharyngeal carcinoma: analysis of the patterns of relapse and the results of withholding elective neck irradiation. Int J Radiat Oncol Biol Phys. 1989, 17: 1183-1190.PubMed
118.
Sanghera P, McConkey C, Ho K-F, Glaholm J, Hartley A: Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2007, 67: 1342-1351.PubMed
119.
Sanguineti G, Califano J, Stafford E, Fox J, Koch W, Tufano R, Sormani MP, Forastiere A: Defining the risk of involvement for each neck nodal level in patients with early t-stage node-positive oropharyngeal carcinoma. Int J Radiat Oncol. 2009, 74: 1356-1364.
120.
Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma [http://​informahealthcar​e.​com.​bvs.​cilea.​it/​doi/​abs/​10.​3109/​0001648090291408​0]
121.
Studer G, Peponi E, Kloeck S, Dossenbach T, Huber G, Glanzmann C: Surviving hypopharynx–larynx carcinoma in the era of IMRT. Int J Radiat Oncol. 2010, 77: 1391-1396.
122.
Lee NY, O’Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG: Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys. 2007, 69: 459-468.PubMed
123.
Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St. Rose S, Barbachano Y, A’Hern R, Tanay M, Hickey J, Nicol R, Newbold KL, Harrington KJ, Nutting CM: Dose-escalated intensity-modulated radiotherapy is feasible and May improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol. 2012, 82: 539-547.
124.
Nakamura K, Shioyama Y, Sasaki T, Ohga S, Saku M, Urashima Y, Yoshitake T, Nakashima T, Kuratomi Y, Komune S, Terashima H, Honda H: Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int J Radiat Oncol. 2005, 62: 680-683.
125.
Okamoto M, Takahashi H, Yao K, Inagi K, Nakayama M, Nagai H: Clinical impact of using chemoradiotherapy as a primary treatment for hypopharyngeal cancer. Acta Oto-Laryngol Suppl 2002, 547:11–14.,
126.
Lefebvre J-L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. JNCI J Natl Cancer Inst. 1996, 88: 890-PubMed
127.
Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB, for the EORTC Head and Neck Cancer Cooperative Group and the EORTC Radiation Oncology Group: Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy. J Natl Cancer Inst. 2009, 101: 142-152.PubMedCentralPubMed
128.
Gupta GP, Lee NY: Hypopharyngeal Carcinoma. In Target Vol Delin Field Setup. Edited by Lee NY, Lu JJ. Berlin Heidelberg: Springer; 2013:29–34.
129.
Lapeyre M, Bailly C, Toledano I, Montalban A, Russier M: Cancer de l’hypopharynx et du larynx : proposition de sélection et délimitation des volumes cibles microscopiques péri-tumoraux (aires ganglionnaires exclues). Cancer/Radiothérapie. 2010, 14 (Supplement 1): S43-S51.
130.
Amatsu M, Mohri M, Kinishi M: Significance of retropharyngeal node dissection at radical surgery for carcinoma of the hypopharynx and cervical esophagus. Laryngoscope. 2001, 111: 1099-1103.PubMed
131.
Laskar SG, Baijal G, Murthy V, Chilukuri S, Budrukkar A, Gupta T, Agarwal JP: Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of Two different cohorts of dose-fractionation schedules from a single institution. Clin Oncol. 2012, 24: e180-e186.
132.
Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M: Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2006, 64: 77-82.PubMed
133.
Trotti A, Pajak T, Emami B, Hammond E, Jones C, Morrison W, Sagar S, Ridge J, Fu KK, Ang K: A randomized trial of hyperfractionation versus standard fractionation in T2 squamous cell carcinoma of the vocal cord. Int J Radiat Oncol. 2006, 66: S15-
134.
Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, Le Maître A, Bernier J, Horiot JC, Maillard E, Pajak TF, Poulsen MG, Bourredjem A, O’Sullivan B, Dobrowsky W, Andrzej H, Skladowski K, Hay JH, Pinto LH, Fu KK, Fallai C, Sylvester R, Pignon JP, MARCH Collaborative Group: Hyperfractionated or Accelerated Radiotherapy for Head and Neck Cancer. Volume 12 Art. No.: CD002026. DOI: 10.1002/14651858.CD002026.pub2. John Wiley & Sons, Ltd; 2010. http://​onlinelibrary.​wiley.​com/​enhanced/​doi/​10.​1002/​14651858.​CD002026.​pub2. Accessed 7 Jan 2015.
135.
Russi EG, Sanguineti G, Chiesa F, Franco P, Succo G, Merlotti A, Ansarin M, Melano A, Alterio D, Pergolizzi S, Buglione M, Reali A, Ricardi U, Corvò R: Is there a role for postoperative radiotherapy following open partial laryngectomy when prognostic factors on the pathological specimen are unfavourable? A survey of head and neck surgical/radiation oncologists. Acta Otorhinolaryngol Ital Organo Uff Della Soc Ital Otorinolaringol E Chir Cerv-facc. 2013, 33: 311-319.
136.
Spriano G, Antognoni P, Sanguineti G, Sormani M, Richetti A, Ameli F, Piantanida R, Luraghi R, Magli A, Corvo R, Tordiglione M, Vitale V: Laryngeal long-term morbidity after supraglottic laryngectomy and postoperative radiation therapy. Am J Otolaryngol. 2000, 21: 14-21.PubMed
137.
Chao CKS, Apisarnthanarax S, Ozyigit G: Practical Essentials of Intensity Modulated Radiation Therapy. 2005, Lippincott Williams & Wilkins, Philadelphia, 2
138.
Hansen EK, Roach M: Handbook of Evidence-Based Radiation Oncology. 2nd ed. New York Heidelberg Dordrecht London: Springer; 2010.
139.
Kutta H, Steven P, Paulsen F: Anatomical definition of the subglottic region. Cells Tissues Organs. 2006, 184: 205-214.PubMed
140.
Eisbruch A: Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine. Oncologist. 2007, 12: 975-977.PubMed
141.
Chera BS, Amdur RJ, Morris CG, Mendenhall WM: Carotid-sparing intensity-modulated radiotherapy for early-stage squamous cell carcinoma of the true vocal cord. Int J Radiat Oncol Biol Phys. 2010, 77: 1380-1385.PubMed
142.
Rosenthal DI, Fuller CD, Barker JL, Mason B, Garcia JA, Lewin JS, Holsinger FC, Stasney CR, Frank SJ, Schwartz DL, Morrison WH, Garden AS, Ang KK: Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1–2 glottic cancer. Int J Radiat Oncol. 2010, 77: 455-461.
143.
Van den Bogaert W, Ostyn F, van der Schueren E: The different clinical presentation, behaviour and prognosis of carcinomas originating in the epilarynx and the lower supraglottis. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1983, 1: 117-131.
144.
Lengelé B, Hamoir M, Scalliet P, Grégoire V: Anatomical bases for the radiological delineation of lymph node areas. Major collecting trunks, head and neck. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2007, 85: 146-155.
145.
De Bree R, Leemans CR, Silver CE, Robbins KT, Rodrigo JP, Rinaldo A, Takes RP, Shaha AR, Medina JE, Suárez C, Ferlito A: Paratracheal lymph node dissection in cancer of the larynx, hypopharynx, and cervical esophagus: The need for guidelines. Head Neck. 2011, 33: 912-916.PubMed
146.
Daly ME, Chen AM, Bucci MK, El-Sayed I, Xia P, Kaplan MJ, Eisele DW: Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol. 2007, 67: 151-157.
147.
Wiegner EA, Daly ME, Murphy JD, Abelson J, Chapman CH, Chung M, Yu Y, Colevas AD, Kaplan MJ, Fischbein N, Le Q-T, Chang DT: Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Int J Radiat Oncol. 2012, 83: 243-251.
148.
Hoppe BS, Wolden SL, Zelefsky MJ, Mechalakos JG, Shah JP, Kraus DH, Lee N: Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: Technique, early outcomes, and toxicity. Head Neck. 2008, 30: 925-932.PubMed
149.
Spratt D, Cabanillas R, Lee NY: The Paranasal Sinuses. In Target Vol Delin Field Setup. Edited by Lee NY, Lu JJ. Berlin Heidelberg: Springer; 2013:45–48.
150.
Zanation AM, Ferlito A, Rinaldo A, Gore MR, Lund VJ, McKinney KA, Suárez C, Takes RP, Devaiah AK: When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol. 2010, 267: 1667-1671.PubMedCentralPubMed
151.
Jiang GL, Ang KK, Peters LJ, Wendt CD, Oswald MJ, Goepfert H: Maxillary sinus carcinomas: natural history and results of postoperative radiotherapy. Radiother Oncol. 1991, 21: 193-200.PubMed
152.
Le Q-T, Fu KK, Kaplan MJ, Terris DJ, Fee WE, Goffinet DR: Lymph node metastasis in maxillary sinus carcinoma. Int J Radiat Oncol. 2000, 46: 541-549.
153.
Fukumitsu N, Okumura T, Mizumoto M, Oshiro Y, Hashimoto T, Kanemoto A, Hashii H, Ohkawa A, Moritake T, Tsuboi K, Tabuchi K, Wada T, Hara A, Sakurai H: Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or Recurrent Nasal Cavity and Paranasal Sinus Carcinoma Treated with Proton Beam. Int J Radiat Oncol 2011, 83:704–711.
154.
Zenda S, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, Hayashi R, Kishimoto S, Ogino T: Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol. 2011, 81: 1473-1478.
155.
Garden AS, El-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ: Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol. 1997, 37: 79-85.
156.
Terhaard CHJ, Lubsen H, Van der Tweel I, Hilgers FJM, Eijkenboom WMH, Marres HAM, Tjho-Heslinga RR, De Jong JMA, Roodenburg Jl N: Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004, 26: 681-693.PubMed
157.
Andry G, Hamoir M, Locati LD, Licitra L, Langendijk JA: Management of salivary gland tumors. Expert Rev Anticancer Ther. 2012, 12: 1161-1168.PubMed
158.
Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW: Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: What is the role of elective neck irradiation?. Int J Radiat Oncol. 2007, 67: 988-994.
159.
Armstrong JG, Harrison LB, Thaler HT, Friedlander-Klar H, Fass DE, Zelefsky MJ, Shah JP, Strong EW, Spiro RH: The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer. 1992, 69: 615-619.PubMed
160.
Zbären P, Schüpbach J, Nuyens M, Stauffer E, Greiner R, Häusler R: Carcinoma of the parotid gland. Am J Surg. 2003, 186: 57-62.PubMed
161.
Jones AS, Cook JA, Phillips DE, Roland NR: Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer. 1993, 72: 1756-1761.PubMed
162.
Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, Califano JA, Tufano RP, Koch WM: Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck. 2008, 30: 898-903.PubMed
163.
Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ: Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck. 1998, 20: 739-744.PubMed
164.
Nieder C, Gregoire V, Ang KK: Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?. Int J Radiat Oncol. 2001, 50: 727-733.
165.
Koch WM, Bhatti N, Williams MF, Eisele DW: Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2001, 124: 331-333.
166.
Kinder KJ, Lavertu P, Yao M: Positron emission tomography in head and neck squamous cell carcinoma of unknown primary. PET Clin. 2012, 7: 443-452.
167.
Safa AA, Tran LM, Rege S, Brown CV, Mandelkern MA, Wang MB, Sadeghi A, Juillard G: The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am. 1999, 5: 214-218.PubMed
168.
Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, Glisson BS, Chao KSC, Schwartz DL, Chronowski GM, El-Naggar AK, Garden AS: Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson cancer center outcomes and patterns of failure. Int J Radiat Oncol. 2010, 78: 1005-1010.
169.
Riaz N, Chen A, Lee NY: Squamous cell carcinoma of unknown primary in the head and neck. In Target Vol Delin Field Setup. Edited by Lee NY, Lu JJ. Berlin Heidelberg: Springer; 2013:65–71.
170.
Beldì D, Jereczek-Fossa BA, D’Onofrio A, Gambaro G, Fiore MR, Pia F, Chiesa F, Orecchia R, Krengli M: Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: retrospective analysis of 113 patients. Int J Radiat Oncol. 2007, 69: 1051-1058.
171.
Mendenhall WM, Mancuso AA, Amdur RJ, Stringer SP, Villaret DB, Cassisi NJ: Squamous cell carcinoma metastatic to the neck from an unknown head and neck primary site. Am J Otolaryngol. 2001, 22: 261-267.PubMed
172.
Villeneuve H, Després P, Fortin B, Filion E, Donath D, Soulières D, Guertin L, Ayad T, Christopoulos A, Nguyen-Tan PF: Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy. Int J Radiat Oncol. 2012, 82: 1866-1871.
173.
Shoushtari A, Saylor D, Kerr K-L, Sheng K, Thomas C, Jameson M, Reibel J, Shonka D, Levine P, Read P: Outcomes of patients with head-and-neck cancer of unknown primary origin treated with intensity-modulated radiotherapy. Int J Radiat Oncol. 2011, 81: e83-e91.
174.
Ligey A, Gentil J, Créhange G, Montbarbon X, Pommier P, Peignaux K, Truc G, Maingon P: Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an unknown primary. Radiother Oncol. 2009, 93: 483-487.PubMed
Metadata
Title
Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group
Authors
Anna Merlotti
Daniela Alterio
Riccardo Vigna-Taglianti
Alessandro Muraglia
Luciana Lastrucci
Roberto Manzo
Giuseppina Gambaro
Orietta Caspiani
Francesco Miccichè
Francesco Deodato
Stefano Pergolizzi
Pierfrancesco Franco
Renzo Corvò
Elvio G Russi
Giuseppe Sanguineti
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-014-0264-9

Other articles of this Issue 1/2014

Radiation Oncology 1/2014 Go to the issue

Research

Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma

Research

IMRT credentialing for prospective trials using institutional virtual phantoms: results of a joint European Organization for the Research and Treatment of Cancer and Radiological Physics Center project

Research

IMRT with 18FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer

Research

Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results

Research

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

Research

Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors